Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Millennium Pharmaceuticals
Woman and Man Max 99 years
Millennium Pharmaceuticals, Inc
Update Il y a 4 ans
A Phase 2 Trial of MLN8237, an Oral Aurora A Kinase Inhibitor, in Adult Patients with Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome
To estimate antitumor activity of MLN8237 as measured by response rate in patients with AML and high-grade MDS
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Millennium Pharmaceuticals, Inc
Update Il y a 4 ans
Study to determine whether adding MLN9708 to the combination of lenalidomide and dexamethasone improves survival in patients who have been newly diagnosed with multiple myeloma and have not received previous anti-myeloma treatment
To determine whether the addition of oral MLN9708 to lenalidomide and dexamethasone improves progression-free survival (PFS) in patients with newly-diagnosed multiple myeloma (NDMM)
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Millennium Pharmaceuticals, Inc
Update Il y a 4 ans
To determine whether adding MLN9708 to the combination of lenalidomide and dexamethasone improves survival in patients with multiple myeloma whose disease is no longer responding or has not responded, to previous treatment
To determine whether the addition of oral ixazomib to the background therapy of lenalidomide and dexamethasone improves progression-free survival (PFS) in patients with relapsed and/or refractory mult...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Millennium Pharmaceuticals, Inc
Update Il y a 4 ans
Phase 4 Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
To assess the antitumor efficacy of single-agent brentuximab vedotin (1.8 mg/kg administered intravenously every 3 weeks) as measured by the overall objective response rate (ORR) in patients with rela...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Millennium Pharmaceuticals, Inc
Update Il y a 4 ans
A trial to evaluate MLN0264 for the treatment of pancreatic tumors which have a protein called Guanylyl Cyclase C (GCC) present, in patients that have been treated previously and in whom the cancer is advanced or has spread
To evaluate the overall response rate (ORR) of patients with advanced or metastatic GCC-positive adenocarcinoma of the pancreas treated with MLN0264
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman
Between 18 years
and 99 years
Millennium Pharmaceuticals
Update Il y a 4 ans
C14008 : Essai de phase 1-2 comprenant une première partie évaluant l’association de l’alisertib et du paclitaxel chez des patientes ayant un cancer du sein, suivie d’une seconde partie randomisée, évaluant l’association de l’alisertib et du paclitaxel par rapport au paclitaxel seul, chez des patientes ayant un cancer épithélial de l’ovaire, des trompes de Fallope ou primitif du péritoine. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer l’efficacité de l’association de l’alisertib et du paclitaxel par rapport au paclitaxel seul, chez des patientes ayant un cancer épithélial de l’ovaire, des tromp...
Country
France
organs
Sein
,
Ovaire
,
Appareil génital féminin - autres
,
Péritoine
Specialty
Thérapies Ciblées
,
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Millennium Pharmaceuticals, Inc
Update Il y a 4 ans
A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Ulcerative Colitis
Primary Objective for the Induction Phase • To determine the effect of MLN0002 induction treatment on clinical response at 6 weeks Primary Objective for the Maintenance Phase • To determine th...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Millennium Pharmaceuticals
Update Il y a 4 ans
C14007 : Essai de phase 1, en escalade de doses, évaluant la tolérance du MLN8237, un inhibiteur de kinase Aurora A, chez des patients ayant un cancer non hématologique, suivi d’un essai de phase 2 évaluant l’activité anti tumorale du MLN8237, chez des patients ayant un cancer du poumon, du sein, de la tête et du cou ou un cancer gastro-oesophagien. [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer la tolérance et l’efficacité du MLN8237, un inhibiteur de kinase Aurora A, chez des patients ayant un cancer du poumon, du sein, de la tête et du cou ou un cancer...
Country
France
organs
Sein
,
Poumon, type à petites cellules
,
Poumon, type non à petites cellules
,
Oesophage
,
Estomac
,
Tête et cou
,
Tumeurs solides
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman Max 99 years
Millennium Pharmaceuticals, Inc
Update Il y a 4 ans
A Phase 2 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in the Treatment of Patients with Platinum-Refractory or Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
To estimate the objective antitumor response rate of MLN8237 using the Response Evaluation Criteria in Solid tumors (RECIST criteria) or CA 125 criteria in patients with platinum-refractory or platinu...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Millennium Pharmaceuticals, Inc
Update Il y a 4 ans
A Phase 2a Magnetic Resonance Imaging Study of the Safety and Efficacy of MLN1202 in patients with Multiple Sclerosis
The primary objectives of this study are to: •Determine the safety and tolerability of MLN1202 in patients with RRMS. •Determine the efficacy of MLN1202 in patients with RRMS by comparing the mean num...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
Next